Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2953 entries
Sorted by: Best Match Show Resources per page
Is it lawful and ethical to prioritize racial minorities for COVID-19 vaccines?

Minority STEM training

Gostin LO, Schmidt H, Williams MA.
GSID: TLyVpezbiXwJ
H Schmidt, LO Gostin, MA Williams - Jama, 2020 - jamanetwork.com

… waiting in line at a health care facility. Second, public health agencies could not provide … through community health centers, many of which serve largely urban minority populations. …

Cite
Schmidt, H., Gostin, L. O., & Williams, M. A. (2020). Is it lawful and ethical to prioritize racial minorities for COVID-19 vaccines?. Jama, 324(20), 2023-2024.
Schmidt, Harald, Lawrence O. Gostin, and Michelle A. Williams. "Is it lawful and ethical to prioritize racial minorities for COVID-19 vaccines?." Jama 324.20 (2020): 2023-2024.
Copy Download .nbib Format: MLA
Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review

Non-school settings

Bardach A, Ciapponi A.
GSID: 8Ui7LWVEFQ4J
A Ciapponi, A Bardach, A Mazzoni, T Alconada… - medRxiv, 2021 - ncbi.nlm.nih.gov

Background Pregnant women with COVID-19 are at an increased risk of severe COVID-19 illness as well as adverse pregnancy and birth outcomes. Many countries are vaccinating or …

Cite
Ciapponi, A., Bardach, A., Mazzoni, A., Alconada, T., Anderson, S., Argento, F. J., ... & Buekens, P. M. (2021). Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review. medRxiv.
Ciapponi, Agustín, et al. "Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review." medRxiv (2021).
Copy Download .nbib Format: MLA
Correlates of COVID-19 vaccination status among college students

Latinx/Hispanic ethnicity

Kawaguchi E.
GSID: MxXtLPSTctgJ
M Nicolo, E Kawaguchi, A Ghanem-Uzqueda, AE Kim… - medRxiv, 2021 - medrxiv.org

Objectives. Despite the widespread availability of COVID-19 vaccines in the United States, vaccine hesitancy remains high among certain groups. This study examined the correlates of …

Cite
Nicolo, M., Kawaguchi, E., Ghanem-Uzqueda, A., Kim, A. E., Soto, D., Deva, S., ... & Unger, J. B. (2021). Correlates of COVID-19 vaccination status among college students. medRxiv.
Nicolo, Michele, et al. "Correlates of COVID-19 vaccination status among college students." medRxiv (2021).
Copy Download .nbib Format: MLA
Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Nguyen LC, Bakerlee CW, McKelvey TG, Rose SM, Norman AJ, Joseph N, Manheim D, McLaren MR, Jiang S, Barnes CF, Kinniment M, Foster D, Darton TC, Morrison J.
PMID: 32628748
Clin Infect Dis. 2021 Feb 16;72(4):710-715. doi: 10.1093/cid/ciaa935.

Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss 3 potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding...

Cite
Nguyen LC, Bakerlee CW, McKelvey TG, et al. Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development. Clin Infect Dis. 2021;72(4):710-715doi: 10.1093/cid/ciaa935.
Nguyen, L. C., Bakerlee, C. W., McKelvey, T. G., Rose, S. M., Norman, A. J., Joseph, N., Manheim, D., McLaren, M. R., Jiang, S., Barnes, C. F., Kinniment, M., Foster, D., Darton, T. C., & Morrison, J. (2021). Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 72(4), 710-715. https://doi.org/10.1093/cid/ciaa935
Nguyen, Linh Chi, et al. "Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 72,4 (2021): 710-715. doi: https://doi.org/10.1093/cid/ciaa935
Nguyen LC, Bakerlee CW, McKelvey TG, Rose SM, Norman AJ, Joseph N, Manheim D, McLaren MR, Jiang S, Barnes CF, Kinniment M, Foster D, Darton TC, Morrison J. Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development. Clin Infect Dis. 2021 Feb 16;72(4):710-715. doi: 10.1093/cid/ciaa935. PMID: 32628748; PMCID: PMC7454474.
Copy Download .nbib Format: NLM
The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Plotkin SA.
PMID: 32674139
Clin Infect Dis. 2021 Feb 16;72(4):716-717. doi: 10.1093/cid/ciaa1013.

No abstract available.

Cite
Plotkin SA. The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Clin Infect Dis. 2021;72(4):716-717doi: 10.1093/cid/ciaa1013.
Plotkin, S. A. (2021). The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 72(4), 716-717. https://doi.org/10.1093/cid/ciaa1013
Plotkin, Stanley A. "The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 72,4 (2021): 716-717. doi: https://doi.org/10.1093/cid/ciaa1013
Plotkin SA. The Value of Human Challenges in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. Clin Infect Dis. 2021 Feb 16;72(4):716-717. doi: 10.1093/cid/ciaa1013. PMID: 32674139; PMCID: PMC7543275.
Copy Download .nbib Format: NLM
Which Vaccine? The Cost of Religious Freedom in Vaccination Policy.

Journal of bioethical inquiry

Giubilini A, Savulescu J, Wilkinson D.
PMID: 34940937
J Bioeth Inq. 2021 Dec;18(4):609-619. doi: 10.1007/s11673-021-10148-6. Epub 2021 Dec 23.

We discuss whether and under what conditions people should be allowed to choose which COVID-19 vaccine to receive on the basis of personal ethical views. The problem arises primarily with regard to some religious groups' concerns about the connection...

Cite
Giubilini A, Savulescu J, Wilkinson D. Which Vaccine? The Cost of Religious Freedom in Vaccination Policy. J Bioeth Inq. 2021;18(4):609-619doi: 10.1007/s11673-021-10148-6.
Giubilini, A., Savulescu, J., & Wilkinson, D. (2021). Which Vaccine? The Cost of Religious Freedom in Vaccination Policy. Journal of bioethical inquiry, 18(4), 609-619. https://doi.org/10.1007/s11673-021-10148-6
Giubilini, Alberto, et al. "Which Vaccine? The Cost of Religious Freedom in Vaccination Policy." Journal of bioethical inquiry vol. 18,4 (2021): 609-619. doi: https://doi.org/10.1007/s11673-021-10148-6
Giubilini A, Savulescu J, Wilkinson D. Which Vaccine? The Cost of Religious Freedom in Vaccination Policy. J Bioeth Inq. 2021 Dec;18(4):609-619. doi: 10.1007/s11673-021-10148-6. Epub 2021 Dec 23. PMID: 34940937; PMCID: PMC8696246.
Copy Download .nbib Format: NLM
Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution.

International immunopharmacology

Pieri M, Nicolai E, Ciotti M, Nuccetelli M, Sarubbi S, Pelagalli M, Bernardini S.
PMID: 34862126
Int Immunopharmacol. 2021 Nov 27;108406. doi: 10.1016/j.intimp.2021.108406. Epub 2021 Nov 27.

The global strategy to control coronavirus disease is based on the availability of COVID-19 vaccines. More information about response to a single dose vaccine could help to better understand and optimize the management of the vaccine campaign. Workers from...

Cite
Pieri M, Nicolai E, Ciotti M, et al. Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution. Int Immunopharmacol. 2021;108406doi: 10.1016/j.intimp.2021.108406.
Pieri, M., Nicolai, E., Ciotti, M., Nuccetelli, M., Sarubbi, S., Pelagalli, M., & Bernardini, S. (2021). Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution. International immunopharmacology, 108406. https://doi.org/10.1016/j.intimp.2021.108406
Pieri, Massimo, et al. "Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution." International immunopharmacology vol. (2021): 108406. doi: https://doi.org/10.1016/j.intimp.2021.108406
Pieri M, Nicolai E, Ciotti M, Nuccetelli M, Sarubbi S, Pelagalli M, Bernardini S. Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution. Int Immunopharmacol. 2021 Nov 27;108406. doi: 10.1016/j.intimp.2021.108406. Epub 2021 Nov 27. PMID: 34862126; PMCID: PMC8626226.
Copy Download .nbib Format: NLM
Perceptions of COVID-19 vaccines in a predominantly Hispanic patient population from the Texas-Mexico border.

Journal of the American Pharmacists Association : JAPhA

Amundson CJ, Sias JJ, Frietze GA.
PMID: 34862142
J Am Pharm Assoc (2003). 2021 Nov 05; doi: 10.1016/j.japh.2021.11.003. Epub 2021 Nov 05.

BACKGROUND: Compared with nationwide averages, Hispanic individuals have experienced lower routine vaccination rates and have been disproportionately hospitalized for coronavirus disease 2019 (COVID-19). Few, if any, studies have examined the health beliefs surrounding the COVID-19 vaccines and adult vaccines...

Cite
Amundson CJ, Sias JJ, Frietze GA. Perceptions of COVID-19 vaccines in a predominantly Hispanic patient population from the Texas-Mexico border. J Am Pharm Assoc (2003). 2021;doi: 10.1016/j.japh.2021.11.003.
Amundson, C. J., Sias, J. J., & Frietze, G. A. (2021). Perceptions of COVID-19 vaccines in a predominantly Hispanic patient population from the Texas-Mexico border. Journal of the American Pharmacists Association : JAPhA, . https://doi.org/10.1016/j.japh.2021.11.003
Amundson, Collin J, et al. "Perceptions of COVID-19 vaccines in a predominantly Hispanic patient population from the Texas-Mexico border." Journal of the American Pharmacists Association : JAPhA vol. (2021). doi: https://doi.org/10.1016/j.japh.2021.11.003
Amundson CJ, Sias JJ, Frietze GA. Perceptions of COVID-19 vaccines in a predominantly Hispanic patient population from the Texas-Mexico border. J Am Pharm Assoc (2003). 2021 Nov 05; doi: 10.1016/j.japh.2021.11.003. Epub 2021 Nov 05. PMID: 34862142; PMCID: PMC8570390.
Copy Download .nbib Format: NLM
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.

European journal of cancer (Oxford, England : 1990)

Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Gutiérrez T, Tagliamento M, Lambertini M, Villarreal-Garza C.
PMID: 34794855
Eur J Cancer. 2021 Oct 26; doi: 10.1016/j.ejca.2021.10.014. Epub 2021 Oct 26.

BACKGROUND: Patients with cancer are considered a priority group for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of contracting severe Coronavirus Disease 2019 (COVID-19). However, limited data exist regarding the efficacy of immunisation in...

Cite
Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2021;doi: 10.1016/j.ejca.2021.10.014.
Becerril-Gaitan, A., Vaca-Cartagena, B. F., Ferrigno, A. S., Mesa-Chavez, F., Barrientos-Gutiérrez, T., Tagliamento, M., Lambertini, M., & Villarreal-Garza, C. (2021). Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990), . https://doi.org/10.1016/j.ejca.2021.10.014
Becerril-Gaitan, Andrea, et al. "Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis." European journal of cancer (Oxford, England : 1990) vol. (2021). doi: https://doi.org/10.1016/j.ejca.2021.10.014
Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Gutiérrez T, Tagliamento M, Lambertini M, Villarreal-Garza C. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2021 Oct 26; doi: 10.1016/j.ejca.2021.10.014. Epub 2021 Oct 26. PMID: 34794855; PMCID: PMC8548030.
Copy Download .nbib Format: NLM
Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, Grifoni A, Sette A, Kaiser L, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS.
PMID: 34791081
Clin Infect Dis. 2021 Nov 17; doi: 10.1093/cid/ciab954. Epub 2021 Nov 17.

BACKGROUND: Patients treated with anti-CD20 therapy are particularly at risk of developing severe COVID-19, however little is known regarding COVID-19 vaccine effectiveness in this population.METHODS: This prospective observational cohort study assesses humoral and T-cell responses after vaccination with 2...

Cite
Madelon N, Lauper K, Breville G, et al. Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021;doi: 10.1093/cid/ciab954.
Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., Grifoni, A., Sette, A., Kaiser, L., Siegrist, C. A., Finckh, A., Lalive, P. H., Didierlaurent, A. M., & Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciab954
Madelon, Natacha, et al. "Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2021). doi: https://doi.org/10.1093/cid/ciab954
Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, Grifoni A, Sette A, Kaiser L, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS. Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2021 Nov 17; doi: 10.1093/cid/ciab954. Epub 2021 Nov 17. PMID: 34791081.
Copy Download .nbib Format: NLM
Spotlight on Vaccines: Pandemic May Open Gateway to Improve Vaccination Rates in Texas.

Texas medicine

Price S.
PMID: 34855954
Tex Med. 2021 Mar 01;117(3):20-25.

The uneven rollout of COVID-19 vaccines in December created at least one bright spot for Texas physicians: It highlighted how the state could make vaccination more efficient.

Cite
Price S. Spotlight on Vaccines: Pandemic May Open Gateway to Improve Vaccination Rates in Texas. Tex Med. 2021;117(3):20-25
Price, S. (2021). Spotlight on Vaccines: Pandemic May Open Gateway to Improve Vaccination Rates in Texas. Texas medicine, 117(3), 20-25.
Price, Sean. "Spotlight on Vaccines: Pandemic May Open Gateway to Improve Vaccination Rates in Texas." Texas medicine vol. 117,3 (2021): 20-25.
Price S. Spotlight on Vaccines: Pandemic May Open Gateway to Improve Vaccination Rates in Texas. Tex Med. 2021 Mar 01;117(3):20-25. PMID: 34855954.
Copy Download .nbib Format: NLM
The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation.

Vaccines

Rzymski P, Borkowski L, Drąg M, Flisiak R, Jemielity J, Krajewski J, Mastalerz-Migas A, Matyja A, Pyrć K, Simon K, Sutkowski M, Wysocki J, Zajkowska J, Fal A.
PMID: 33535716
Vaccines (Basel). 2021 Feb 01;9(2). doi: 10.3390/vaccines9020109.

COVID-19 vaccinations are about to begin in various countries or are already ongoing. This is an unprecedented operation that is also met with a loud response from anti-vaccine communities-currently using all available channels to manipulate public opinion. At the...

Cite
Rzymski P, Borkowski L, Drąg M, et al. The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines (Basel). 2021;9(2)doi: 10.3390/vaccines9020109.
Rzymski, P., Borkowski, L., Drąg, M., Flisiak, R., Jemielity, J., Krajewski, J., Mastalerz-Migas, A., Matyja, A., Pyrć, K., Simon, K., Sutkowski, M., Wysocki, J., Zajkowska, J., & Fal, A. (2021). The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines, 9(2), . https://doi.org/10.3390/vaccines9020109
Rzymski, Piotr, et al. "The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation." Vaccines vol. 9,2 (2021). doi: https://doi.org/10.3390/vaccines9020109
Rzymski P, Borkowski L, Drąg M, Flisiak R, Jemielity J, Krajewski J, Mastalerz-Migas A, Matyja A, Pyrć K, Simon K, Sutkowski M, Wysocki J, Zajkowska J, Fal A. The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. Vaccines (Basel). 2021 Feb 01;9(2). doi: 10.3390/vaccines9020109. PMID: 33535716; PMCID: PMC7912910.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2953 entries